EX-10.21





 Exhibit 10.21 

Forte Biosciences Inc. 

March 16, 2020 
 Antony Riley 

Dear Tony: 
 I am pleased to provide this offer
for you to serve Forte Biosciences, Inc. (the “Company”) as its Chief Financial Officer, reporting to the Chief Executive Officer. If you decide to accept this offer, the terms of this offer will be effective as of
March 23, 2020 (the “Effective Date”). You will receive an annual base salary of $340,000 (the “Base Salary”), which will be paid periodically in accordance with the Company’s normal payroll
practices and be subject to the usual, required withholdings. Your Base Salary will be subject to review and adjustments will be made based upon the Company’s normal performance review practices. 

Commencing on the Effective Date, you will be eligible to receive a target annual bonus equal to 35% of your Base Salary then in effect upon
achievement of performance objectives to be determined by the Board of Directors of the Company (the “Board”) in its sole discretion (the “Target Bonus”). The Target Bonus, or any portion thereof, will
be paid, less applicable withholdings, as soon as practicable after the Board determines that the Target Bonus has been earned, but in no event shall the Target Bonus be paid after the later of (i) the fifteenth (15th) day of the third (3rd)
month following the close of the Company’s fiscal year (which currently is December 31st) in which the Target Bonus is earned or (ii) March 15 following the calendar year in which
the Target Bonus is earned. Any bonuses will be subject to your continued employment with the Company through the date the bonus is earned. 

Commencing on the date immediately following the closing of the Merger (as such term is defined in that certain Agreement and Plan of Merger
and Reorganization by and among Tocagen, Inc., its merger subsidiary and the Company, dated on or about the date hereof), in the event that your employment is terminated (i) by the Company for reasons other than “Cause” (as defined
below), death, or disability or (ii) by you for “Good Reason” (as defined below) (either a “Qualifying Termination”), and in any case subject to you signing and not revoking a standard form of release of claims
with the Company within 60 days following your employment termination date (the “Release”), you will receive (A) cash payments in the form of continuation of your base salary at the rate in effect at the time of
termination, less applicable withholdings, payable in accordance with the Company’s standard payroll practices for a period of nine (9) months following your employment termination date, with the first payment to be made no later than ten
(10) days following the effective date of the Release (subject to any delay as may be required under the Section 409A paragraph below), (B) reimbursement for the cost of continuation of health coverage for you and your eligible dependents
pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) until the earlier of (x) nine (9) months following your termination of employment or (y) the date you and your eligible
dependents are no longer eligible for COBRA; provided, however, if, at the time of your termination of employment, the Company determines that providing the COBRA reimbursement in this paragraph would result in a violation of law or an excise tax to
the Company, then the Company instead will pay a lump sum payment equal to nine (9) months of your estimated monthly COBRA premiums, grossed-up for any applicable taxes, within ten (10) days
following the effective date of the Release (subject to any delay as may be required under the Section 409A paragraph below), and (C) if such Qualifying Termination occurs on or within 12 months following a “Change of Control”
(as defined in the Company’s 2018 Equity Incentive 












 
Plan), vesting acceleration of your Option (as defined below) in an amount equal to 100% of the then-unvested portion of your Option (or any unvested shares previously acquired under that
Option). For clarity, prior to the closing of the Merger, none of the benefits set forth in the paragraph shall apply. 
 It is the intent
of this offer letter that all payment and benefits hereunder comply with or be exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and any guidance promulgated thereunder and
any applicable state law requirements (“Section 409A”) so that none of the payments and benefits to be provided under this offer letter will be subject to the additional tax imposed under
Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be exempt or so comply. Each payment and benefit payable under this offer letter is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. You and the Company agree to work together in good faith to consider amendments to this offer letter and to take such reasonable actions which are necessary,
appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to you under Section 409A. No termination pay or benefits to be paid or provided to you, if any, pursuant to this offer letter
that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A (together, “Deferred Compensation”) or otherwise would be exempt from
Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be paid or otherwise provided until you have a “separation from service” within the meaning of Section 409A.
Any termination payments or benefits under this offer letter that would be considered Deferred Compensation will be paid on, or, in the case of installments, will not commence until, the sixty-first (61st) day following your separation from service,
or, if later, the Delayed Payment Date (as defined below). Further, if at the time of your termination of employment, you are a “specified employee” within the meaning of Section 409A, payment of such Deferred Compensation will be
delayed to the extent necessary to avoid the imposition of the additional tax imposed under Section 409A, which generally means that you will receive payment on the first payroll date that occurs on or after the date that is six (6) months
and one (1) day following your termination of employment, or your death, if earlier (the “Delayed Payment Date”). 

For purposes of this offer letter “Cause” means: (i) a material breach of any of your obligations to the Company
or any of its affiliates under the terms of this offer letter or your At Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement; (ii) your gross negligence or willful failure or refusal to perform your duties;
(iii) any material act of personal dishonesty taken by you and intended to result in substantial personal enrichment of you at the expense of the Company or its affiliates; (iv) any willful or intentional act that could reasonably be
expected to injure the reputation, business, or business relationships of the Company or its affiliates; (v) perpetration of an intentional and knowing fraud against or affecting the company or any customer, supplier, client, agent, or employee
thereof; (vi) your conviction of a felony or any crime involving fraud, dishonesty or moral turpitude; or (vii) your termination in connection with a dissolution, wind-down or liquidation of the Company, including as part of a voluntary or
involuntary bankruptcy or insolvency proceedings; with respect to any of the foregoing (other than clauses (vi) or (vii)), the Board shall be required to give you written notice of any termination for “Cause” with a detailed
description of any alleged breach together with a 30 day ability to cure any such breach, unless such breach is non-curable. 

For purposes of this offer letter, “Good Reason” means one of the following has occurred without your written consent:
(A) a material breach by the Company of any of the covenants in this offer letter; (B) any reduction of your base salary or compensation (including bonus opportunity); or (C) any material change in the geographic location at which you
must principally perform services; it being understood that a change in such geographic location of less than 50 miles will not be deemed material for these 

  
 -2- 













 
purposes. You will not resign for “Good Reason” without first providing the Company with written notice of the acts or omissions constituting the grounds for “Good Reason”
within 90 days following the initial occurrence of the event giving rise to “Good Reason” and a reasonable cure period of thirty (30) days following the date the Company receives such notice during which such condition must not have
been cured, and you must resign from your employment with the Company within 30 days following the end of the cure period if uncured. 
 If
you decide to accept this offer, the Company shall recommend that the Board grant to you an option to purchase, pursuant to an option agreement, 175,000 shares of Common Stock, par value $0.0001 per share, of the Company (the “Common
Stock”) at a price per share equal to the fair market value per share of the Common Stock on the date of grant, as determined by the Board (the “Option”). It is anticipated that 50,000 shares of the Option will
be granted prior to the closing of the Merger and 125,000 shares of the Option will be granted following the closing of the Merger, and in the event the date of grant occurs following the closing of the Merger, the number of shares of Common Stock
subject to the Option shall be adjusted to take into account the exchange ratio in the Merger. Subject to the vesting acceleration terms described in this offer letter, 25% of the shares subject to the option shall vest 12 months after the date your
vesting begins subject to your continuing employment with the Company, and no shares shall vest before such date. The remaining shares shall vest monthly over the next 36 months in equal monthly amounts subject to your continuing employment with the
Company. Any shares acquired upon exercise of the Option will be subject to the terms and conditions of the Company’s Equity Incentive Plan and option agreement to be entered into between you and the Company. 

If you accept this offer of employment, from and after the Effective Date, you will be entitled to participate in any employee benefit plans
hereafter maintained by the Company of general applicability to other senior executives of the Company, including, without limitation, any group medical, dental, vision, disability, life insurance plans maintained by the Company, subject to the
terms and conditions of the applicable plans. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time. 

The Company is excited about continuing a beneficial and productive relationship. Nevertheless, you should be aware that your employment with
the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to conclude its
employment relationship with you at any time, with or without cause, and with or without notice. We request that, in the event of resignation, you give the Company at least two weeks’ notice. 

We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment that
may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any such agreements will not prevent you from performing the duties of your position and you
represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which
the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly, you agree not to bring any third party confidential
information to the Company, including that of your former employer, and that in performing your duties for the Company you will not in any way utilize any such information. 

  
 -3- 













 As a condition of your employment, you are also required to sign and comply with an At Will
Employment, Confidential Information, Invention Assignment and Arbitration Agreement which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. In the event of any dispute or claim relating to or arising out of our employment relationship, you and the Company agree that any and all disputes between you and
the Company shall be fully and finally resolved by binding arbitration, and you are waiving any and all rights to a jury trial. Please note that we must receive your signed Agreement before your first day of employment. 

To accept the Company’s offer, please sign and date this letter in the space provided below. This offer letter, along with any agreements
relating to proprietary rights between you and the Company, set forth the terms of your employment with the Company and supersede any prior representations or agreements including, but not limited to, any representations made during your
recruitment, interviews or pre-employment negotiations, whether written or oral. This offer letter, including, but not limited to, its at-will employment provision, may
not be modified or amended except by a written agreement signed by the Chief Executive Officer and you. 
 We look forward to your favorable
reply and working with you at the Company. 

  
 -4- 













 
			
	Sincerely,
		
	        	 	 /s/ Paul A. Wagner, Ph.D.

		 	 Paul A. Wagner, Ph.D., Chief Executive Officer



  
  

			
	Agreed to and accepted:
		
	Signature:	 	/s/ Antony Riley
		
	Printed Name:	 	Antony Riley
		
	Date:	 	March 16, 2020


  
 -5-